Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.

Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). Combining sorafenib with another treatment, to improve overall survival (OS) within an acceptable safety profile, might be the next step forward in the management of patients with advanced HCC. We aimed to assess whether a combination of sorafenib and a statin improved survival in patients with HCC. The objective of the PRODIGE-11 trial was to compare the respective clinical outcomes of the sorafenib-pravastatin combination (arm A) versus sorafenib alone (arm B) in patients with advanced HCC. Child-Pugh A patients with advanced HCC who were naive to systemic treatment (n = 323) were randomly assigned to sorafenib-pravastatin combination (n = 162) or sorafenib alone (n = 161). The primary endpoint was OS; secondary endpoints were progression-free survival, time to tumor progression, time to treatment failure, safety, and quality of life. After randomization, 312 patients received at least 1 dose of study treatment. After a median follow-up of 35 months, 269 patients died (arm A: 135; arm B: 134) with no difference in median OS between treatments arms (10.7 months vs. 10.5 months; hazard ratio = 1.00; p = 0.975); no difference was observed in secondary survival endpoints either. In the univariate analysis, the significant prognostic factors for OS were CLIP score, performance status, and quality of life scores. The multivariate analysis showed that the only prognostic factor for OS was the CLIP score. The main toxicity was diarrhea (which was severe in 11% of patients in arm A, and 8.9% in arm B), while severe nausea-vomiting was rare, and no toxicity-related deaths were reported. Adding pravastatin to sorafenib did not improve survival in patients with advanced HCC. Sorafenib has proven efficacy for the treatment of patients with advanced hepatocellular carcinoma. However, overall survival remains poor in these patients, so we were interested to see if the addition of a statin, pravastatin, improved outcomes in patients with advanced HCC. This randomized-controlled trial demonstrated that the sorafenib-pravastatin combination did not improve overall survival in this study population compared to sorafenib alone. Clinical trial number: NCT01075555. Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Citation

Jean-Louis Jouve, Thierry Lecomte, Olivier Bouché, Emilie Barbier, Faiza Khemissa Akouz, Ghassan Riachi, Eric Nguyen Khac, Isabelle Ollivier-Hourmand, Maryline Debette-Gratien, Roger Faroux, Anne-Laure Villing, Julien Vergniol, Jean-François Ramee, Jean-Pierre Bronowicki, Jean-François Seitz, Jean-Louis Legoux, Jacques Denis, Sylvain Manfredi, Jean-Marc Phelip, PRODIGE-11 investigators/collaborators. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. Journal of hepatology. 2019 Sep;71(3):516-522

Mesh Tags

Substances

PMID: 31125576

search → result